Screener
Scholar Rock SRRK Early Research — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Scholar Rock in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Scholar Rock’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:20 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336732
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| External R&D expense - apitegromab | 22,948 | 27,956 | 43,209 | 47,257 |
| External R&D expense - SRK-181 | 9 | 792 | 45 | 1,902 |
| External R&D expense - SRK-439 | 3,760 | 2,575 | 5,519 | 6,854 |
| External R&D expense - Early research and other | 1,610 | 2,227 | 2,820 | 3,682 |
| External expense - G&A | 16,597 | 14,952 | 32,729 | 23,895 |
| Other segment items(2) | 6,573 | 6,273 | 13,082 | 11,531 |
| Equity-based compensation expense | 19,662 | 24,433 | 37,907 | 37,846 |
| Depreciation and amortization expense | 297 | 417 | 632 | 810 |
Item 1. Financial Statements
FAQ
- What is Scholar Rock's early research — research and development expense?
- Scholar Rock (SRRK) reported early research — research and development expense of $1.61M in Q2 2026.
- How has Scholar Rock's early research — research and development expense changed year-over-year?
- Scholar Rock's early research — research and development expense decreased by 27.7% year-over-year, from $2.23M to $1.61M.
- What is the long-term trend for Scholar Rock's early research — research and development expense?
- Over 2 years (2023 to 2025), Scholar Rock's early research — research and development expense has grown at a 22.3% compound annual growth rate (CAGR), from $4.46M to $6.68M.
- What does early research — research and development expense mean?
- This metric represents the total operating costs specifically allocated to the discovery and preclinical development activities within the early-stage research segment. It captures the investment in scientific exploration, target validation, and initial drug candidate characterization before a program advances to formal clinical trials. Monitoring this expenditure provides insight into the company's commitment to building its long-term pipeline and the intensity of its innovation efforts.
Ask your AI about Scholar Rock's early research — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude